نتایج جستجو برای: 177lu psma
تعداد نتایج: 2383 فیلتر نتایج به سال:
PSMA-TRT is approved for mCRPC based upon demonstrated overall survival (OS) advantage. However, even after pre-selection by PSMA imaging, not all patients respond (54% without PSA50 response in the VISION study). In addition to dose (which likely related both target expression and amount of radioactivity administered), prognostic genomic factors that may relate radiosensitivity exist. Collecti...
In spite of the hazard due to the radiation exposure, preparation of 90Y- and 177Lu-labelled radiopharmaceuticals is still mainly performed using manual procedures. In the present study the performance of a commercial automatic synthesizer based on disposable cassettes for the labelling of 177Lu- and 90Y-DOTA-conjugated biomolecules (namely, DOTATOC and PSMA-617) was evaluated and compared to a...
amount of 177Lu for every cycle? Although this is now the standard approach, it is reasonable to ask whether advantages might accrue to administering different amounts of radioactivity at different treatment cycles. Kulkarni et al. from the Zentralklinik Bad Berka (Germany) reported on “Serial dosimetry during 177Lu-PSMA radioligand therapy in the same patient” [316]. The authors performed dosi...
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)-positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time-activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to t...
BACKGROUND Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively sho...
Introduction. Prostate cancer (PC), according to the results for 2019, is second most frequently diagnosed malignant tumor in men living Russian Federation. There a significant proportion of patients with advanced (III-IV stages) prostate - up 50 %, while metastatic accounts 18.1 % patients. Popularization Moscow City Healthcare clinical practice innovative technologies managing castration-resi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید